Protagonist Secures $200M Rusfertide Opt-Out Fee and $50M ICOTYDE Milestone
Protagonist posted $56.4 million in Q1 license revenue—including a $50 million ICOTYDE milestone—and achieved $3.8 million net income with $0.06 EPS. The company secured a $200 million rusfertide opt-out fee, holds $620 million cash for runway through 2028, and anticipates multiple Phase 1 and 2 readouts by year-end.
1. FDA Approval and ICOTYDE Milestone
In March 2026 the FDA approved ICOTYDE for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment to Protagonist. Under the collaboration with Johnson & Johnson, Protagonist is eligible for up to $580 million in additional regulatory and sales milestones and tiered royalties of 6% to 10% on global net sales.
2. Rusfertide Priority Review and Opt-Out Election
Protagonist’s rusfertide NDA was accepted with Priority Review and a PDUFA action date in Q3 2026. On April 28 the company exercised its opt-out right under the Takeda collaboration, receiving a $200 million fee and boosting its eligibility for an additional $200 million opt-out payment, a $75 million approval milestone, up to $775 million in sales milestones and 14%–29% tiered royalties.
3. Pipeline Advancements
The oral IL-17 antagonist peptide PN-881 is on track to complete its Phase 1 trial by mid-2026 with Phase 2 initiation expected by year-end. Triple agonist peptide PN-477 sc and oral formulations are set to begin Phase 1 in mid-2026 and Q1 2027, respectively, alongside ongoing IND-enabling studies for PN-458 and PN-8047 and discovery projects in oral peptide programs.
4. Financial Positions and Q1 Results
As of March 31, 2026, Protagonist held $620.3 million in cash, cash equivalents and marketable securities, supporting operations through at least 2028. Q1 results included $56.4 million in license and collaboration revenue, $46.7 million in R&D expense, $13.3 million in G&A expenses, and net income of $3.8 million (EPS $0.06) versus a $11.7 million loss (EPS -$0.19) a year earlier.